Bim Mediates Germ Cell Death During Ovarian Development.
Seng H. Liew(Prince of Wales Hospital), Karla J. Hutt(Discovery Institute), Michelle Myers(Nucana (United Kingdom)), Philippe Bouillet(Walter and Eliza Hall Institute of Medical Research), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Jock K. Findlay, J. B. Kerr(Barrie Urology Group), Andreas Strasser(The University of Melbourne)
Cited by 0
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis.
|The EMBO Journal|1995|788
Methods for quantifying follicular numbers within the mouse ovary
|Reproduction|2004|764